Substantiating the concerns about recombinant human activated protein C use in sepsis

Crit Care Med. 2004 Dec;32(12):2542-3. doi: 10.1097/01.ccm.0000148090.94378.6a.
No abstract available

Publication types

  • Comparative Study
  • Editorial
  • Comment

MeSH terms

  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase IV as Topic
  • Critical Care / methods
  • Critical Illness
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Intensive Care Units
  • Male
  • Prognosis
  • Protein C / adverse effects*
  • Protein C / therapeutic use*
  • Recombinant Proteins / adverse effects*
  • Recombinant Proteins / therapeutic use*
  • Risk Assessment
  • Sepsis / diagnosis
  • Sepsis / drug therapy*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated